In Table S3 of PRODIGE 24, locoregional alone (13.4) or LR + distant recurrence (9.7%) made up 23% of all the patients (as opposed to 28% having isolated distance recurrence), cumulative 54.2% DFS event
Yes, those numbers are better than Gemcitabine - 18% LR alone, 17.1% LR+ distant, or 35% of...